Physician profile
Jonathan D Black
NPI 1700106184
$329,412.09
in general payments reported to CMS, 2019-2025
40 companies · $48K in 2025
The $48K reported for 2025 was more than what 97% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $11K · 2021: $54K · 2022: $95K · 2023: $64K · 2024: $57K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $142K · Food and Beverage: $9,229 · Travel and Lodging: $8,868 · Education: $8,184 · Gift: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $142,291.83 |
| Food and Beverage | $9,228.51 |
| Travel and Lodging | $8,868.01 |
| Education | $8,183.99 |
| Gift | $559.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $189,237.44 | 2021-2025 | Surgicel Nu-Knit, Ethicon, Evarrest |
| Ethicon US, LLC | $76,986.67 | 2021-2025 | Vistaseal, Ethicon, Evarrest |
| Ethicon INC. | $20,316.31 | 2021-2024 | Surgicel Nu-Knit, Ethicon, Evarrest |
| Intuitive Surgical, INC. | $12,785.69 | 2021-2025 | Da Vinci Surgical System |
| Aspira Women'S Health INC | $10,842.26 | 2020-2021 | |
| Hologic Sales and Service, LLC | $8,145.88 | 2021-2024 | Novasure, Acessa Provu System, Myosure Tissue Removal Device |
| Hologic INC | $4,000.00 | 2022 | |
| Gynesonics, INC. | $1,038.39 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $815.13 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Myriad Genetic Laboratories, INC. | $553.41 | 2022-2025 | Myrisk, Precisetumor |
| Astrazeneca Pharmaceuticals LP | $532.09 | 2020-2025 | Lynparza, Imfinzi |
| Abbvie INC. | $434.19 | 2019-2025 | |
| Eisai INC. | $401.07 | 2021-2025 | |
| Glaxosmithkline, LLC. | $392.73 | 2020-2025 | Jemperli, Zejula |
| Biotissue Holdings INC. | $363.25 | 2024-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acessa Health INC. | $350.00 | 2024 | Acessa Provu System |
| Astellas Pharma US INC | $314.47 | 2023-2025 | Veozah |
| Davol INC. | $282.79 | 2024-2025 | Phasix Mesh |
| Seagen INC. | $263.22 | 2021-2023 | Tivdak |
| Pfizer INC. | $236.93 | 2024-2025 | |
| Meditrina | $144.22 | 2020-2024 | |
| Sumitomo Pharma America, INC. | $125.00 | 2023 | Myfembree |
| Minerva Surgical, INC | $112.76 | 2023 | |
| Allergan, INC. | $98.80 | 2019-2020 | |
| Clovis Oncology, INC. | $89.87 | 2021-2022 | |
| Conmed Corporation | $81.31 | 2022 | |
| Medtronic, INC. | $77.07 | 2022 | |
| Tesaro, INC. | $62.34 | 2019 | |
| Caris Mpi, INC. | $56.89 | 2025 | Mi Cancer Seek |
| Fennec Pharmaceuticals, INC. | $37.12 | 2024 | Pedmark |
| Coopersurgical, INC. | $36.95 | 2023-2025 | Wallach Cryosurgical Equipment, Ally II Ups |
| Biom'Up France Sas | $33.07 | 2021 | |
| Caldera Medical, INC | $28.56 | 2022 | |
| Coherus Oncology, INC. | $26.07 | 2022 | |
| Olympus America INC. | $23.61 | 2023 | Olympus |
| Teleflex LLC | $22.58 | 2025 | Quikclot |
| Amgen INC. | $18.19 | 2020 | |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Genentech USA, INC. | $15.03 | 2019 | |
| Axonics, INC. | $14.38 | 2023 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.